Emollient creams for face and body improve eczema in children with atopic dermatitis and help to restablish the normal skin flora

ISRCTN ISRCTN24922464
DOI https://doi.org/10.1186/ISRCTN24922464
Secondary identifying numbers Nutra-01-2015
Submission date
14/10/2015
Registration date
16/10/2015
Last edited
13/05/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Eczema, also known as dermatitis, is a long-term medical condition which causes the skin to become dry, itchy and irritated. Atopic eczema (AE) is the most common type of eczema, particularly in children. It can appear anywhere on the body, but it is usually found on the face, trunk (chest and back) and around the inside of the elbows or knees. This type of eczema is called “atopic” because sufferers are more sensitive to allergens (substances which can cause an allergic reaction). The exact cause of AE is not fully understood, however it is thought that their skin does not produce as many protective oils as it should do and so the skin loses water easily. This means that the protective barrier of the skin is not as good as it should be, and so is more vulnerable to skin infections. Staphylococcus aureus is a common bacterium which lives on the skin. In people with AE, these bacteria are able to get into the skin, triggering an immune response causing “flare-ups” of symptoms. Many eczema treatments work by moisturising the skin with creams (emollients), which help to restore the skin barrier. The aim of this study is to look at the effectiveness of a new hydrating emollient cream containing a protein called isoleucine, which stimulates the skin to produce antimicrobial peptides (proteins which fight microorganisms like bacteria).

Who can participate?
Children with mild to moderate atopic eczema.

What does the study involve?
Participants are given two skin creams to apply twice a day for 8 weeks. The first cream is specially designed to be applied to the face and the second cream is specially designed for the body. At the start of the study and then after 4 and 8 weeks of using the creams, the children are examined to find out whether their eczema has improved. They are also interviewed to find out how itchy their eczema is. At the start of the study and again after 8 weeks of using the creams, the skin in the affected areas is swabbed so that the amount of Staphylococcus aureus can be measured.

What are the possible benefits and risks of participating?
Potential benefits of participating are that the creams may help to improve the symptoms of AE. There are no risks of participating in the study.

Where is the study run from?
Pediatric Clinic, University of Pavia (Italy)

When is the study starting and how long is it expected to run for?
January 2015 to September 2015

Who is funding the study?
Isdin (Italy)

Who is the main contact?
Dr Massimo Milani

Contact information

Dr Massimo Milani
Public

Viale Abruzzi 3
Milan
20126
Italy

ORCiD logoORCID ID 0000-0001-7559-1202

Study information

Study designProspective assessor-blinded single-arm multi-centre study
Primary study designInterventional
Secondary study designSingle-arm prospective assessor blinded trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleBarrier Repair Therapy in Atopic Eczema: effects of isoleucine, rhamnosoft and niacinamide facial and body creams on clinical, itch and Staphylococcus aureus skin colonization: A prospective assessor-blinbed study
Study objectivesTo evaluate the clinical effects (signs of inflammation and the anti-itch effects) and Staphylococcus aureus colonization of two creams (one specifically formulated for application on face and the other formulated for the body) containing emollient, hydrating and and a Anti microbial Peptides promoting agent (Iso-leucine) in children with mid to moderate atopic eczema.
Ethics approval(s)IRB Pavia Hospital, 18/12/2014
Health condition(s) or problem(s) studiedAtopic Eczema
InterventionParticipants are provided with two products concurrently to apply twice daily for 8 consecutive weeks:

1. Participants apply 2 Finger Tip Units (1g) of the Nutratopic pro-AMP facial cream containing rhamnosoft, niacinamede and isoleucine to the face
2. Participants apply 5 Finger Tip Units of the Nutratopic pro-AMP body cream containing rhamnosoft, niacinamede and isoleucine the the body (upper, lower arms and trunk).

At baseline, week 4 and week 8, eczema severity, scoring redness, thickness scratching and lichenification are assessed. Skin swabs are taken for detection of S. aureus were obtained from lesional skin at baseline and at month 2.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)1. Nutratopic pro-AMP facial cream 2. Nutratopic pro-AMP body cream
Primary outcome measure1. Eczema severity is measured using the Eczema Severity Index score (4-point scale) at baseline, week 4 and week 8
2. Itch intensity evaluated by a 10-cm Visual Analogue Scale at baseline, week 4 and week 8
Secondary outcome measuresStaphylococcus aureus skin colonization is obtained from lesions using skin swabs at baseline and 2 months.
Overall study start date01/01/2015
Completion date30/09/2015

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit2 Years
Upper age limit18 Years
SexBoth
Target number of participants45
Total final enrolment45
Key inclusion criteria1. Aged between 2 and 18 years
2. Mild to moderate atopic eczema according to Hanifin diagnostic criteria
Key exclusion criteria1. Severe form of atopic eczema
2. Use of corticosteroids, calcineurin inhibitors or systemic or topical antibiotics in the 4 weeks prior to enrollement
Date of first enrolment02/01/2015
Date of final enrolment30/06/2015

Locations

Countries of recruitment

  • Italy

Study participating centre

Pediatric Clinic, University of Pavia
IRCCS Policlinico "S. Matteo" Foundation
Pavia
20125
Italy

Sponsor information

Isdin
Industry

Viale Abruzzi 3
Milan
20123
Italy

Funders

Funder type

Industry

Isdin

No information available

Results and Publications

Intention to publish date31/12/2015
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planPlanned publication in an indexed international scientific journal (Pediatric Allergy and Immunology).
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 30/01/2016 13/05/2021 Yes No

Editorial Notes

13/05/2021: The following changes have been made:
1. Publication reference added.
2. The final enrolment number has been added from the reference.